1. Patients who received adjuvant S-1 had prolonged overall survival and relapse-free survival compared to those who were managed with...
1. At week 16, all rocatinlimab groups reported significant improvements in eczema severity. 2. Most treatment-related adverse events were mild-to-moderate,...
Click to read this study in The Lancet Oncology.
1. Global cure was achieved in 59% of the rezafungin group compared to 61% of the caspofungin group. 2. There...
Click to read this study in JAMA Oncology.
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections...
Click to read this study in JAMA Network Open.
1. Incidence of total adverse events and specific adverse events were similar between the emraclidine groups and placebo. 2. There...
1. Risk of hospital admission was lower in the ferric derisomaltose group versus usual care. 2. Treatment-related adverse events were...
1. Compared to placebo, participants on aprocitentan had a greater reduction in office systolic blood pressure at four weeks and...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.